Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR T Cells in R/R B-Cell Malignancies
NCT04943016Phase 1Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Jul 2021
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of UCD19 CAR-T in B cell malignancies, sponsored by National Taiwan University Hospital. Primary endpoints: Proportion of products successfully manufactured meeting the established release criteria at 3 years, Incidence and severity of adverse events at 3 years and 2 more. Status: unknown.
02
Drugs
UCD19 CAR-T
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT04943016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04943016.